Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B836
- Development stage
- Preclinical
- Lead developer
- Nanolattix
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
B836 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by Nanolattix using the Biolattix technology platform. It is designed to simultaneously target Human Epidermal Growth Factor Receptor 2 (HER2) and Tissue Factor (TF). By targeting two distinct antigens, B836 aims to overcome resistance mechanisms associated with single-antigen HER2 ADCs, such as tumor heterogeneity and antigen downregulation. Preclinical studies have demonstrated enhanced binding and internalization compared to single-target ADCs, as well as superior anti-tumor efficacy in models with low HER2 expression. GLP safety studies in cynomolgus monkeys indicated a favorable safety profile with no drug-related ocular or systemic toxicity at doses up to 5 mg/kg.
- Other names
- Double anti-B836-ADC-Nanolattix-ADC-bispecific antibody-Breast cancer-Colorectal cancer-Stomach cancer
02
Targets
F3 (Tissue factor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on B836.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B836.